Sitravatinib (formerly known as MGCD516; MG516) is a novel and potent multi-kinase inhibitor targeting multiple RTKs (Receptor tysosine kinases) such as c-Kit, PDGFRβ, PDGFRα, c-Met, and Axl with potential anticancer activity.

Telatinib mesylate (also known as Bay 57-9352 mesylate) is a potent and orally bioactive VEGFR2, VEGFR3, PDGFα, and c-Kit inhibitor with potential anticancer activity.

Brivanib (formerly BMS-540215; BMS540215) is a novel, investigational, oral and ATP-competitive inhibitor of VEGFR2 with potential anticancer activity.

SU 5214 is a modulator of tyrosine kinase signal transduction.

TG 100801 (TG-100801; TG100801) is an ester prodrug of TG-100572 (TG 100572).

Vandetanib (formerly also known as ZD6474; trade name Caprelsa) is a highly potent, orally bioavailable, and selective inhibitor of VEGFR2 with potential anticancer activity.

Ponatinib (formerly known as AP24534; trade name Iclusig) is a novel, orally bioavailable multi-targeted kinase inhibitor with potent antitumor activity.

SU 5205 is a VEGFR2 inhibitor.

Pamufetinib (TAS-115) mesylate, the mesylate salt of Pamufetinib (TAS115; TAS 115), is an inhibitor of VEGFR and c-MET with anticancer activity.

Apatinib mesylate, the mesylate salt of apatinib, is a potent, orally bioavailable, and selective inhibitor of the VEGF (vascular endothelial growth factor receptor) signaling pathway with IC50 of 1 nM for VEGFR2.